Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-07-18
2006-07-18
Shukla, Ram R. (Department: 1632)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S325000
Reexamination Certificate
active
07078510
ABSTRACT:
The methods and compositions of the present invention find use in altering cardiac-preferred expression in transgenic animals. The compositions of the invention include isolated nucleic acid molecules, expression cassettes, animal cells, transgenic animals, and transgenic mice. The transgenic animals of the invention exhibit inducible cardiac preferred expression of a nucleotide sequence of interest. The methods allow generation of transgenic animals with altered cardiac preferred expression of the nucleotide sequence of interest. In particular, the invention provides a method for altering the susceptibility of a transgenic animal to cardiopathy. A transgenic animal of the invention finds use in identifying anti-cardiopathic compounds.
REFERENCES:
patent: 6353151 (2002-03-01), Leinwand et al.
patent: WO 00/78119 (2000-12-01), None
Rindt H, An in vivo analysis of transcriptional elements in the mouse alpha myosin heavy chain gene promoter, 1995, Transgenic Res. vol. 4, pp. 397-405.
Verma IM, Gene Therapy: Twenty-first century medicine, 2005, Annu. Rev. Biochem. vol. 74, pp. 711-738.
Parekh-Olmedo H, Gene therapy progress and prospects: targeted gene repair, 2005, Gene Therapy, vol. 12, pp. 639-646.
Concalves M, A concise peer into the background, initial thoughts, and practices of human gene therapy, 2005, BioEssays, vol. 27, pp. 506-517.
Robbins et al., Mouse Embryonic Stem Cells Express the Cardiac Myosin Heavy Chain Genes during Development in Vitro, The Journal of Biological Chemistry, vol. 265, No. 20, Jul. 15, 1990 Issue, pp. 11905-11909, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A., copyright 1990.
Subramaniam et al., Tissue-specific Regulation of the a-Myosin Heavy Chain Gene Promoter in Transgenic Mice, The Journal of Biological Chemistry, vol. 266, No. 36, Dec. 25, 1991 Issue, pp. 24613-24620, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A., copyright 1991.
Subramaniam et al., Transgenic Analysis of the Thyroid-responsive Elements in the a-Cardiac Myosin Heavy Chain Gene Promoter, The Journal of Biological Chemistry, vol. 268, No. 6, Feb. 25, 1993 Issue, pp. 4331-4336, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A., copyright 1993.
Dorn II et al., Myosin heavy chain regulation and myocyte contractile depression after LV hypertrophy in aortic-banded mice, Special Communication, vol. 0363-6135/94, pp. H400-H405, The American Physiological Society, copyright 1994.
Palermo et al., Transgenic Remodeling of the Contractile Apparatus in the Mammalian Heart, Circulation Research, 1996: 78:504-509, American Heart Assoc., U.S.A., c 1996.
Sanbe et al, Abnormal Cardiac Structure and Function in Mice Expressing Nonphosphorylatable Cardiac Regulatory Myosin Light Chain 2, The Journal of Biological Chemistry, vol. 274, No. 30, Jul. 23, 1990 Issue, pp. 21085-21094, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A., copyright 1999.
Sanbe et al., Examining the in Vivo Role of the Amino Terminus of the Essential Myosin Light Chain, The Journal of Biological Chemistry, vol. 276, No. 35, Aug. 31, 2001 Issue, pp. 32682-32686, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A., copyright 2001.
James et al., Transgenic Rabbits Expressing Mutant Essential Light Chain do not Develop Hypertrophic Cardiomyopathy, J Mol Cell Cardiol 00.1-10 (2002), Elsevier Science Ltd., U.S.A., copyright 2002.
Sanbe et al., Reengineering Inducible Cardiac-Specific Transgenesis With an Attenuated Myosin Heavy Chain Promoter, Circulation Research, 2003;92:609) American Heart Association, U.S.A., copyright 2003.
Rahkonen et al, “Characterization of the murine TIMP4 gene, localization within intron 5 of the synapsin 2 gene and tissue distribution of the mRNA,” Biochimica et Biophysica Acta, Aug. 19, 2002, p. 45-abstract, vol. 1577(1).
Charron et al. “Cooperative Interaction between GATA-4 and GATA-6 Regulates Myocardial Gene Expression,” Molecular and Cellular Biology, Jun. 1999, p. 4355-4365, vol. 19-6.
Dellow et al. “Identification of novel, cardiac-restricted transcription factors binding to a CACC-box within the human cardiac troponin I promoter,” Cardiovascular Research, Apr. 2001, p. 24-abstract, vol. 50-1.
Grepin et al. “A Hormone-Encoding Gene Identifies a Pathway for Cardiac but Not Skeletal Muscle Gene Transcription,” Molecular and Cellular Biology, May 1994, p. 3115-3129, vol. 14-5.
Kiewitz et al. “Transcriptional Regulation of S100A1 and expression during mouse heart development,” Biochimica et Biophysica Acta, Dec. 20, 2000, p. 207-abstract, vol. 1498-2/3.
Majalahti-Palviainen et al. “Gene Structure of a New Cardiac Peptide Hormone: A Model for Heart-Specific Gene Expression,” Endocrinology, 2000, p. 731-740, vol. 141-2.
Children's Hospital Medical Center
Montanari David A.
Shukla Ram R.
Taft Stettinius & Hollister LLP
LandOfFree
Robust, inducible cardiac preferred expression system for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Robust, inducible cardiac preferred expression system for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Robust, inducible cardiac preferred expression system for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3595963